Clinical Reference Database
Evidence-based documentation on GLP-1 receptor agonist medications. Each article is reviewed by a board-certified endocrinologist and updated regularly to reflect current clinical evidence.
603 Evidence-Based Guides
7 Medications Covered
Monthly Review Cycle
Browse by Medication
Ozempic GLP-1 RA
Injectable GLP-1 receptor agonist for type 2 diabetes and weight management.
Mounjaro GLP-1/GIP
Dual-action incretin mimetic targeting both GLP-1 and GIP receptors.
Wegovy GLP-1 RA
Higher-dose semaglutide specifically approved for chronic weight management.
Semaglutide GLP-1 RA
The active compound in Ozempic, Wegovy, and Rybelsus formulations.
Tirzepatide GLP-1/GIP
Novel dual-incretin molecule used in Mounjaro and Zepbound.
Zepbound GLP-1/GIP
Tirzepatide formulation approved specifically for obesity treatment.
Rybelsus GLP-1 RA
Oral semaglutide tablet for type 2 diabetes management.
Recently Published
A1C Dropped Too Low on Semaglutide: Hypoglycemia Risk Oct 14 A1C Dropped Too Low on Tirzepatide: Hypoglycemia Risk Oct 14 alpha-lipoic acid for Appetite Control After Stopping Ozempic Oct 14 alpha-lipoic acid for Blood Sugar Spikes After Stopping Zepbound Oct 14 alpha-lipoic acid for Cholesterol Management After Stopping Mounjaro Oct 14 alpha-lipoic acid for Energy Levels After Stopping Mounjaro Oct 14 alpha-lipoic acid for Gut Health After Stopping Wegovy Oct 14 alpha-lipoic acid for Insulin Resistance After Stopping Zepbound Oct 14